Literature DB >> 23295736

U-2932: two clones in one cell line, a tool for the study of clonal evolution.

H Quentmeier1, R M Amini, M Berglund, W G Dirks, S Ehrentraut, R Geffers, R A F Macleod, S Nagel, J Romani, M Scherr, M Zaborski, H G Drexler.   

Abstract

Genetic heterogeneity is common in tumors, explicable by the development of subclones with distinct genetic and epigenetic alterations. We describe an in vitro model for cancer heterogeneity, comprising the diffuse large B-cell lymphoma cell line U-2932 which expresses two sets of cell surface markers representing twin populations flow-sorted by CD20 vs CD38 expression. U-2932 populations were traced to subclones of the original tumor with clone-specific immunoglobulin IgVH4-39 hypermutation patterns. BCL6 was overexpressed in one subpopulation (R1), MYC in the other (R2), both clones overexpressed BCL2. According to the combined results of immunoglobulin hypermutation and cytogenetic analysis, R1 and R2 derive from a mother clone with genomic BCL2 amplification, which acquired secondary rearrangements leading to the overexpression of BCL6 (R1) or MYC (R2). Some 200 genes were differentially expressed in R1/R2 microarrays including transcriptional targets of the aberrantly expressed oncogenes. Other genes were regulated by epigenetic means as shown by DNA methylation analysis. Ectopic expression of BCL6 in R2 variously modulated new candidate target genes, confirming dual silencing and activating functions. In summary, stable retention of genetically distinct subclones in U-2932 models tumor heterogeneity in vitro permitting functional analysis of oncogenes against a syngenic background.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23295736     DOI: 10.1038/leu.2012.358

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Authors:  Hakan Köksal; Pierre Dillard; Sarah E Josefsson; Solrun Melkorka Maggadottir; Sylvie Pollmann; Anne Fåne; Yngvild Nuvin Blaker; Klaus Beiske; Kanutte Huse; Arne Kolstad; Harald Holte; Gunnar Kvalheim; Erlend B Smeland; June H Myklebust; Else Marit Inderberg; Sébastien Wälchli
Journal:  Blood Adv       Date:  2019-04-23

2.  Ethical Challenges Using Human Tumor Cell Lines in Cancer Research.

Authors:  Wilhelm G Dirks
Journal:  Recent Results Cancer Res       Date:  2021

3.  BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.

Authors:  Jie Ding; Wilhelm G Dirks; Stefan Ehrentraut; Robert Geffers; Roderick A F MacLeod; Stefan Nagel; Claudia Pommerenke; Julia Romani; Michaela Scherr; Lea A I Vaas; Margarete Zaborski; Hans G Drexler; Hilmar Quentmeier
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

Review 4.  Clonal evolution in hematological malignancies and therapeutic implications.

Authors:  D A Landau; S L Carter; G Getz; C J Wu
Journal:  Leukemia       Date:  2013-08-27       Impact factor: 11.528

5.  N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

Authors:  Philip J Brown; Duncan M Gascoyne; Linden Lyne; Hayley Spearman; Suet Ling Felce; Nora McFadden; Probir Chakravarty; Sharon Barrans; Steven Lynham; Dinis P Calado; Malcolm Ward; Alison H Banham
Journal:  Haematologica       Date:  2016-04-07       Impact factor: 9.941

6.  The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma.

Authors:  Kristy Lee; Matthew R Hart; Margaret M Briehl; Andrew P Mazar; Margaret E Tome
Journal:  Int J Oncol       Date:  2014-04-23       Impact factor: 5.650

7.  Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function.

Authors:  Andre Kleensang; Marguerite M Vantangoli; Shelly Odwin-DaCosta; Melvin E Andersen; Kim Boekelheide; Mounir Bouhifd; Albert J Fornace; Heng-Hong Li; Carolina B Livi; Samantha Madnick; Alexandra Maertens; Michael Rosenberg; James D Yager; Liang Zhao; Thomas Hartung
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

8.  Chromosome 11q23 aberrations activating FOXR1 in B-cell lymphoma.

Authors:  C Pommerenke; V Hauer; M Zaborski; R A F MacLeod; S Nagel; R M Amini; M Berglund; R Geffers; H G Drexler; H Quentmeier
Journal:  Blood Cancer J       Date:  2016-06-10       Impact factor: 11.037

9.  Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation.

Authors:  Hilmar Quentmeier; Claudia Pommerenke; Ole Ammerpohl; Robert Geffers; Vivien Hauer; Roderick A F MacLeod; Stefan Nagel; Julia Romani; Emanuela Rosati; Anders Rosén; Cord C Uphoff; Margarete Zaborski; Hans G Drexler
Journal:  Oncotarget       Date:  2016-09-27

10.  Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Authors:  Wei Liu; Juan Chen; Archito T Tamayo; Changgeng Ruan; Li Li; Shouhao Zhou; Chan Shen; Ken H Young; Jason Westin; Richard E Davis; Shimin Hu; Leonard J Medeiros; Richard J Ford; Lan V Pham
Journal:  Oncotarget       Date:  2017-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.